New Zealand markets open in 6 hours 26 minutes

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4400+0.1700 (+13.39%)
As of 11:33AM EDT. Market open.

Clovis Oncology, Inc.

5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
United States
303 625 5000
https://www.clovisoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees413

Key executives

NameTitlePayExercisedYear born
Mr. Patrick J. Mahaffy MACo-Founder, CEO, Pres & Exec. Director760.93kN/A1963
Dr. Gillian C. Ivers-Read BScCo-Founder, Exec. VP & Chief Regulatory Officer707.06kN/A1954
Mr. Daniel W. MuehlExec. VP & CFO686.05kN/A1964
Mr. Paul Edward GrossExec. VP, Gen. Counsel & Sec.691.88kN/A1965
Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPMExec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer737.5kN/A1968
Dr. Thomas Fuglsang Harding B.Sc., Ph.D.Exec. VP & Chief Scientific OfficerN/AN/A1974
Ms. Breanna BurkartVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Ann BozemanExec. VP of HRN/AN/AN/A
Ms. Anna SussmanVP of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.

Corporate governance

Clovis Oncology, Inc.’s ISS governance QualityScore as of 31 July 2022 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.